nach oben

Current Pulmonology Reports

Erschienen in:

13.07.2020 | Sleeping and Breathing (A Abreu, Section Editor)

Management of Insomnia in Chronic Lung Diseases

verfasst von: Kori Ascher, Alexandre R. Abreu, Alejandro D. Chediak

Erschienen in: Current Pulmonology Reports | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Review the treatment of insomnia in those with chronic lung diseases.

Recent Findings

Cognitive behavioral therapy for insomnia and positive airway pressure, the latter for those with sleep disordered breathing, are effective and safe alternatives to hypnotic therapy. Some new hypnotics improve sleep via mechanisms that theoretically render them safe to use in those afflicted with both insomnia and chronic lung disease.

Summary

Treatment for insomnia may include cognitive behavioral therapy, positive airway pressure, and pharmacotherapy. Computerized cognitive behavioral therapy is a safe and effective treatment alternative for insomnia. Insomnia comorbid with obstructive sleep apnea can respond favorably to positive airway pressure therapy. Prescription hypnotics that affect sleep via modulation of melatonin, histamine, and orexin pathways are theoretically well suited for treatment of insomnia in those with chronic lung diseases. We offer the reader an algorithm to manage a patient with insomnia and chronic lung disease.

Dodge R, Cline MG, Quan SF. The natural history of insomnia and its relationship to respiratory symptoms. Arch Intern Med. 1995;155(16):1797–800.PubMedCrossRef

Association AL. American Lung Association Website. https://www.lung.org/. 2019.

Riemann D. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):17.PubMedCrossRef

Bonnet MH, Arand DL. Hyperarousal and insomnia: state of the science. Sleep Med Rev. 2010;14(1):9–15.PubMedCrossRef

Grima NA, Bei B, Mansfield D. Insomnia theory and assessment. Aust J Gen Pract. 2019;48(4):193–7.PubMedCrossRef

Budhiraja R, Siddiqi TA, Quan SF. Sleep disorders in chronic obstructive pulmonary disease: etiology, impact, and management. J Clin Sleep Med. 2015;11(3):259–70.PubMedPubMedCentralCrossRef

Batal O, Khatib OF, Bair N, Aboussouan LS, Minai OA. Sleep quality, depression, and quality of life in patients with pulmonary hypertension. Lung. 2011;189(2):141–9.PubMedCrossRef

Tomaszek L, Cepuch G, Pawlik L. Evaluation of selected insomnia predictors in adolescents and young adults with cystic fibrosis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018;162(3):212–8.PubMedCrossRef

•• Seda G, Tsai S, Lee-Chiong T. Medication effects on sleep and breathing. Clin Chest Med. 2014;35(3):557–69 This paper reports the normal physiological changes in repiration during sleep and the impact of select medications on repirations during sleep.PubMedCrossRef

10.

Genta PR, Eckert DJ, Gregorio MG, et al. Critical closing pressure during midazolam-induced sleep. J Appl Physiol (1985). 2011;111(5):1315–22.CrossRef

11.

Coyle MA, Mendelson WB, Derchak PA, James SP, Wilson MG. Ventilatory safety of zaleplon during sleep in patients with obstructive sleep apnea on continuous positive airway pressure. J Clin Sleep Med. 2005;1(1):97.PubMedCrossRef

12.

Rosenberg R, Roach JM, Scharf M, Amato DA. A pilot study evaluating acute use of eszopiclone in patients with mild to moderate obstructive sleep apnea syndrome. Sleep Med. 2007;8(5):464–70.PubMedCrossRef

13.

Kryger M, Roth T, Wang-Weigand S, Zhang J. The effects of ramelteon on respiration during sleep in subjects with moderate to severe chronic obstructive pulmonary disease. Sleep Breath. 2009;13(1):79–84.PubMedCrossRef

14.

Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–74.PubMedCrossRef

15.

Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461–71.PubMedCrossRef

16.

Sun H, Palcza J, Rosenberg R, Kryger M, Siringhaus T, Rowe J, et al. Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respir Med. 2015;109(3):416–26.PubMedCrossRef

17.

Douglas NJ, White DP, Weil JV, et al. Hypoxic ventilatory response decreases during sleep in normal men. Am Rev Respir Dis. 1982;125(3):286–9.PubMed

18.

Douglas NJ, White DP, Weil JV, Pickett CK, Zwillich CW. Hypercapnic ventilatory response in sleeping adults. Am Rev Respir Dis. 1982;126(5):758–62.PubMed

19.

Douglas NJ, White DP, Pickett CK, Weil JV, Zwillich CW. Respiration during sleep in normal man. Thorax. 1982;37(11):840–4.PubMedPubMedCentralCrossRef

20.

Smith DRL-C Jr, T. Respiratory physiology during sleep. Sleep Med Clin. 2008;3:497–502.CrossRef

21.

Gothe B, Altose MD, Goldman MD, Cherniack NS. Effect of quiet sleep on resting and CO2-stimulated breathing in humans. J Appl Physiol Respir Environ Exerc Physiol. 1981;50(4):724–30.PubMed

22.

Shigemitsu H, Afshar K. Nocturnal asthma. Curr Opin Pulm Med. 2007;13(1):49–55.PubMedCrossRef

23.

McNicholas WT. Impact of sleep in COPD. Chest. 2000;117(2 Suppl):48S–53S.PubMedCrossRef

24.

Krachman SL, Criner GJ, Chatila W. Cor pulmonale and sleep-disordered breathing in patients with restrictive lung disease and neuromuscular disorders. Semin Respir Crit Care Med. 2003;24(3):297–306.PubMedCrossRef

25.

Bhullar S, Phillips B. Sleep in COPD patients. COPD. 2005;2(3):355–61.PubMedCrossRef

26.

van Manen JG, Bindels PJ, IJzermans CJ, van der Zee JS, Bottema BJ, Schade E. Prevalence of comorbidity in patients with a chronic airway obstruction and controls over the age of 40. J Clin Epidemiol. 2001;54(3):287–93.PubMedCrossRef

27.

•• Mason M, Cates CJ, Smith I. Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database Syst Rev. 2015;7:CD011090 This review paper summarizes 14 different studies involving patients with OSA comparing placebo to either hypnotics, sedatives, or opioids.

28.

Zinchuk AV, Gentry MJ, Concato J, Yaggi HK. Phenotypes in obstructive sleep apnea: a definition, examples and evolution of approaches. Sleep Med Rev. 2017;35:113–23.PubMedCrossRef

29.

Stege G, Vos PJ, van den Elshout FJ, Richard Dekhuijzen PN, van de Ven MJ, Heijdra YF. Sleep, hypnotics and chronic obstructive pulmonary disease. Respir Med. 2008;102(6):801–14.PubMedCrossRef

30.

Kryger M, Wang-Weigand S, Zhang J, Roth T. Effect of ramelteon, a selective MT(1)/MT (2)-receptor agonist, on respiration during sleep in mild to moderate COPD. Sleep Breath. 2008;12(3):243–50.PubMedCrossRef

31.

Cohn MA. Effects of zolpidem, codeine phosphate and placebo on respiration. A double-blind, crossover study in volunteers. Drug Saf. 1993;9(4):312–9.PubMedCrossRef

32.

Cummiskey J, Guilleminault C, Del Rio G, Silvestri R. The effects of flurazepam on sleep studies in patients with chronic obstructive pulmonary disease. Chest. 1983;84(2):143–7.PubMed

33.

Guilleminault C. Benzodiazepines, breathing, and sleep. Am J Med. 1990;88(3A):25S–8S.PubMedCrossRef

34.

Gatti RC, Burke PR, Otuyama LJ, Almeida DR, Tufik S, Poyares D. Effects of zolpidem CR on sleep and nocturnal ventilation in patients with heart failure. Sleep. 2016;39(8):1501–5.PubMedPubMedCentralCrossRef

35.

Carberry JC, Fisher LP, Grunstein RR, Gandevia SC, Mckenzie DK, Butler JE, Eckert DJ. Role of common hypnotics on the phenotypic causes of obstructive sleep apnoea: paradoxical effects of zolpidem. Eur Respir J. 2017;50:1701344. https://doi.org/10.1183/13993003.01344-2017].

36.

Light RW, Merrill EJ, Despars J, Gordon GH, Mutalipassi LR. Doxepin treatment of depressed patients with chronic obstructive pulmonary disease. Arch Intern Med. 1986;146(7):1377–80.PubMedCrossRef

37.

Trauer JM, Qian MY, Doyle JS, Rajaratnam SM, Cunnington D. Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Ann Intern Med. 2015;163(3):191–204.PubMedCrossRef

38.

•• Zachariae R, Lyby MS, Ritterband LM, O’Toole MS. Efficacy of internet-delivered cognitive-behavioral therapy for insomnia - a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2016;30:1–10 This meta anaylsis serves as evidence to support the use of computerized CBT-I across several patient populations.PubMedCrossRef

39.

Ye L, Pien GW, Ratcliffe SJ, Björnsdottir E, Arnardottir ES, Pack AI, et al. The different clinical faces of obstructive sleep apnoea: a cluster analysis. Eur Respir J. 2014;44(6):1600–7.PubMedPubMedCentralCrossRef

40.

Bjornsdottir E, Janson C, Sigurdsson JF, et al. Symptoms of insomnia among patients with obstructive sleep apnea before and after two years of positive airway pressure treatment. Sleep. 2013;36(12):1901–9.PubMedPubMedCentralCrossRef

41.

•• Nguyen XL, Rakotonanahary D, Chaskalovic J, Fleury B. Insomnia related to sleep apnoea: effect of long-term auto-adjusting positive airway pressure treatment. Eur Respir J. 2013;41(3):593–600 This manuscript describes the relationship of sleep apnea to insomnia and the effect of positive pressure therapy on insomnia.PubMedCrossRef

Titel: Management of Insomnia in Chronic Lung Diseases
verfasst von: Kori Ascher
Alexandre R. Abreu
Alejandro D. Chediak
Publikationsdatum: 13.07.2020
Verlag: Springer US
Erschienen in: Current Pulmonology Reports / Ausgabe 3/2020
Elektronische ISSN: 2199-2428
DOI: https://doi.org/10.1007/s13665-020-00253-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Management of Insomnia in Chronic Lung Diseases

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Imaging in Occupational and Environmental Lung Disease

Cannabinoids and Sleep: Helpful or Harmful?

Intrathoracic Manifestations of Sarcoidosis: an Imaging Review Highlighting Atypical Features

Sleep, Obstructive Sleep Apnea, and Chronic Alveolar Hypoventilation in Cystic Fibrosis: Role of Noninvasive Ventilation During Sleep

Current Applications for Nuclear Medicine Imaging in Pulmonary Disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin